Close Menu

Roche

Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.

The sepsis diagnostics market heated up during the year, with FDA clearances for a handful of tests, growing investor interest, and R&D advances in the field.

Horizon will develop NTRK fusion immunohistochemistry reference standards to be used in oncology assays.

Roche's CDx would help Inotrem identify suitable patients for a new therapy it's developing for septic shock, and help physicians identify patients at the highest risk of death.

Labs reported on their work with kits from both Roche and Thermo Fisher, both of which have launched new commercial liquid biopsy products in recent years.

Illumina had filed a series of suits against several companies in the UK starting in 2015, which were recently consolidated into one case.

Roche said the deal will expand its integrated-core-lab position and enable laboratories to make faster, data-driven decisions on operations and processes. 

Using a blood volume of 100 μL, the test demonstrated a sensitivity of 90.2 percent for the diagnosis of blood-culture positive sepsis episodes.

The newly cleared panel has five assays — Roche's Ventana BRAF V600E assay and four other assays that target the MMR proteins MLH1, MSH2, MSH6 and PMS2.

The agreement could lead to a companion diagnostic that supports the development of an Inotrem compound in clinical trials for septic-shock treatment.

Pages